Regulatory FDA hands another rejection to Replimune’s melanoma therapy PharmaphorumReplimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.RegulatoryOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Bayer wins MHRA approval for Kerendia in heart failureNext: FDA issues complete response letter to Replimune’s RP1 for melanoma Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
